Compounds > carbamates
Page last updated: 2024-10-16

carbamates and Fever

carbamates has been researched along with Fever in 9 studies

Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.

Research Excerpts

ExcerptRelevanceReference
" Pyrexia or a spike of fever are well-known AE of BRAF inhibitors, with or without MEK inhibitors, and have been reported to have a high incidence after dabrafenib/trametinib, but not after encorafenib/binimetinib."7.96Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. ( Aiba, S; Amagai, R; Fujimura, T; Hashimoto, A; Kambayashi, Y; Ohuchi, K; Sato, Y; Tanita, K, 2020)
" Pyrexia or a spike of fever are well-known AE of BRAF inhibitors, with or without MEK inhibitors, and have been reported to have a high incidence after dabrafenib/trametinib, but not after encorafenib/binimetinib."3.96Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. ( Aiba, S; Amagai, R; Fujimura, T; Hashimoto, A; Kambayashi, Y; Ohuchi, K; Sato, Y; Tanita, K, 2020)
" Adverse events (AEs) associated with the study medication occurred in 21% of patients."2.74Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. ( Luque, I; Mallolas, J; Pérez-Elias, MJ; Rodríguez-Alcántara, F; Sánchez-Conde, M; Soriano, V, 2009)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19904 (44.44)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's3 (33.33)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Amagai, R1
Fujimura, T1
Kambayashi, Y1
Sato, Y1
Tanita, K1
Ohuchi, K1
Hashimoto, A1
Aiba, S1
Daud, A1
Tsai, K1
Flannery, LE1
Kerr, DM1
Finn, DP1
Roche, M1
Pérez-Elias, MJ1
Sánchez-Conde, M1
Soriano, V1
Mallolas, J1
Luque, I1
Rodríguez-Alcántara, F1
Tavel, JA1
Babiker, A1
Fox, L1
Gey, D1
Lopardo, G1
Markowitz, N1
Paton, N1
Wentworth, D1
Wyman, N1
SCHWARTZ, DT1
SCHETLIN, CF1
ZINTEL, HA1
Riek, RF1
Hirshberg, A1
Lerman, Y1
Jori, A1
Carrara, MC1
Garattini, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
STALWART: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 With and Without Concomitant Antiretroviral Therapy in Patients With HIV-1 Infection and CD4+ Cell Counts of 300 Cells/mm3 or More[NCT00110812]Phase 2267 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

CD4+ Cell Count 2 Years Post-study

(NCT00110812)
Timeframe: two years following close of main study

Interventioncell/mm^3 (Mean)
IL-2499.9
Control557.2

Change in CD4 T Lymphocyte Count

change from baseline to month 12 in CD4 T lymphocyte count (NCT00110812)
Timeframe: At Month 12

Interventioncell/mm^3 (Mean)
No IL-2-8.4
IL-2 Without ART59.0
IL-2 With Pericycle HAART49.8

Change in HIV-RNA Copies/ml (log10) From Baseline to Month 12

(NCT00110812)
Timeframe: month 12

Interventioncopies/ml (log 10) (Mean)
No IL-2-0.64
IL-2 Without ART-0.28
IL-2 With Pericycle HAART-0.09

Commencement of Continuous Antiretroviral Treatment

Number of patients commencing continuous antiretroviral treatment. (NCT00110812)
Timeframe: from randomization through February 28, 2011, the end of the extension phase

Interventionparticipants (Number)
IL-2108
Control66

Discontinuation of IL-2

Patients receiving fewer than 3 cycles of IL-2 by week 32 (NCT00110812)
Timeframe: week 32

Interventionparticipants (Number)
IL-2 Without ART12
IL-2 With Pericycle HAART32

Disease Progression or Death

occurrence of an opportunistic event (AIDS-defining infection or malignancy) or death (NCT00110812)
Timeframe: throughout study, through Feb 28 2009 (median followup of 19 months)

Interventionparticipants (Number)
No IL-21
IL-2 Without ART5
IL-2 With Pericycle HAART7

Fasting Lipid Profile

total fasting cholesterol (NCT00110812)
Timeframe: week 32

Interventionmg/dl (Mean)
No IL-2173.4
IL-2 Without ART167.0
IL-2 With Pericycle HAART164.6

HIV-1 Genotype Changes

Patients who developed mutations associated with antiretroviral drugs. (NCT00110812)
Timeframe: after 3rd cycle of IL-2

Interventionparticipants (Number)
IL-2 With Pericycle HAART2

Initiation of Continuous ART

While patients were not taking ART at baseline or while undergoing IL-2 cycles (other than use of pericycle ART in one of the three groups), some chose to start an ART regimen during the study. (NCT00110812)
Timeframe: from randomization through February 28, 2009

Interventionparticipants (Number)
No IL-234
IL-2 Without ART23
IL-2 With Pericycle HAART14

Mean Change in CD4+ T Lymphocyte Count

Change in CD4 count from baseline to week 32. (NCT00110812)
Timeframe: Week 32

Interventioncell/mm^3 (Mean)
No IL-2-21.8
IL-2 Without ART113.7
IL-2 With Pericycle HAART110.4

Opportunistic Disease or Death During the Trial Extension Phase

Incidence of an opportunistic event (AIDS-defining infection or malignancy) or death between February 28, 2009, when the main study ended, and February 28, 2011, when the extended phase was completed. (NCT00110812)
Timeframe: two years following close of main study

Interventionparticipants (Number)
IL-28
Control3

Plasma HIV RNA

change from baseline in HIV-RNA copies/ml (log10) (NCT00110812)
Timeframe: At Week 32

Interventioncopies/ml (log 10) (Mean)
No IL-2-.39
IL-2 Without ART-.07
IL-2 With Pericycle HAART-.01

SGOT

Number of participants with aspartate aminotransferase (SGOT) greater than 5 times the upper limit of normal (NCT00110812)
Timeframe: week 32

Interventionparticipants (Number)
No IL-21
IL-2 Without ART0
IL-2 With Pericycle HAART0

Thyroid Stimulating Hormone

Number of participants with thyroid stimulating hormone greater than the upper limit of normal (NCT00110812)
Timeframe: week 32

Interventionparticipants (Number)
No IL-23
IL-2 Without ART2
IL-2 With Pericycle HAART7

Undetectable HIV-RNA

Patients with undetectable HIV-RNA levels measured at 24 months after the close of the main study, at the end of the extension phase. (NCT00110812)
Timeframe: 24 months post-trial

Interventionparticipants (Number)
IL-297
Control60

Reviews

1 review available for carbamates and Fever

ArticleYear
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    The oncologist, 2017, Volume: 22, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; C

2017

Trials

2 trials available for carbamates and Fever

ArticleYear
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:1

    Topics: Adult; Carbamates; CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Fever; Fura

2009
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Drug Administration Sc

2010

Other Studies

6 other studies available for carbamates and Fever

ArticleYear
Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib.
    The Journal of dermatology, 2020, Volume: 47, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug Resist

2020
FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats.
    Behavioural brain research, 2018, 11-01, Volume: 353

    Topics: Amidohydrolases; Animals; Anxiety; Benzamides; Carbamates; Central Nervous System Agents; Enzyme Inh

2018
ACUTE FEBRILE REACTION TO MEPHENESIN CARBAMATE.
    JAMA, 1964, Nov-23, Volume: 190

    Topics: Back Pain; Carbamates; Drug Hypersensitivity; Drug Therapy; Fever; Mephenesin; Toxicology

1964
THE CATTLE TICK AND TICK FEVER.
    Australian veterinary journal, 1965, Volume: 41, Issue:7

    Topics: Animals; Australia; Babesiosis; Carbamates; Cattle; Cattle Diseases; Communicable Disease Control; E

1965
Clinical problems in organophosphate insecticide poisoning: the use of a computerized information system.
    Fundamental and applied toxicology : official journal of the Society of Toxicology, 1984, Volume: 4, Issue:2 Pt 2

    Topics: Adolescent; Adult; Aged; Atropine; Carbamates; Child; Child, Preschool; Cholinesterase Inhibitors; C

1984
Importance of noradrenaline synthesis for the interaction between desipramine and reserpine.
    The Journal of pharmacy and pharmacology, 1966, Volume: 18, Issue:9

    Topics: Animals; Carbamates; Desipramine; Dihydroxyphenylalanine; Female; Fever; Norepinephrine; Rats; Reser

1966